References
- Goodman WK, Grice DE, Lapidus KA, Coffey BJ. Obsessive-compulsive
disorder. Psychiatr Clin North Am. 2014;37(3):257-267.
doi:10.1016/j.psc.2014.06.004.
- Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current
therapeutic evidence and potential mechanisms of action. J Psychiatry
Neurosci. 2011;36(2):78-86. doi:10.1503/jpn.100057.
- Carlsson ML. On the role of prefrontal cortex glutamate for the
antithetical phenomenology of obsessive compulsive disorder and
attention deficit hyperactivity disorder. Prog Neuropsychopharmacol
Biol Psychiatry. 2001;25(1):5-26. doi:10.1016/s0278-5846(00)00146-9.
- Chakrabarty K, Bhattacharyya S, Christopher R, Khanna S. Glutamatergic
dysfunction in OCD. Neuropsychopharmacology. 2005;30(9):1735-1740.
doi:10.1038/sj.npp.1300733.
- Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor
signalling: implications for neurodegenerative disorders. Nat Rev
Neurosci. 2010;11(10):682-696. doi:10.1038/nrn2911.
- Karthik S, Sharma LP, Narayanaswamy JC. Investigating the Role of
Glutamate in Obsessive-Compulsive Disorder: Current Perspectives.
Neuropsychiatr Dis Treat. 2020;16:1003-1013. Published 2020 Apr 17.
doi:10.2147/NDT.S211703.
- Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic
review and meta-analysis: Memantine augmentation in moderate to severe
obsessive-compulsive disorder. Psychiatry Res. 2019;282:112602.
doi:10.1016/j.psychres.2019.112602.
- TenĂ³rio MCDS, Graciliano NG, Moura FA, Oliveira ACM, Goulart MOF.
N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel).
2021;10(6):967. Published 2021 Jun 16. doi:10.3390/antiox10060967.
- Raghu G, Berk M, Campochiaro PA, et al. The Multifaceted Therapeutic
Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative
Stress. Curr Neuropharmacol. 2021;19(8):1202-1224.
doi:10.2174/1570159X19666201230144109.
- Sarris J, Oliver G, Camfield DA, et al. N-Acetyl Cysteine (NAC) in the
Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind,
Randomised, Placebo-Controlled Study. CNS Drugs. 2015;29(9):801-809.
doi:10.1007/s40263-015-0272-9.
- Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S,
Akhondzadeh S. N-acetylcysteine augmentation therapy for
moderate-to-severe obsessive-compulsive disorder: randomized,
double-blind, placebo-controlled trial. J Clin Pharm Ther.
2016;41(2):214-219. doi:10.1111/jcpt.12370.
- Costa DLC, Diniz JB, Requena G, et al. Randomized, Double-Blind,
Placebo-Controlled Trial of N-Acetylcysteine Augmentation for
Treatment-Resistant Obsessive-Compulsive Disorder. J Clin Psychiatry.
2017;78(7):e766-e773. doi:10.4088/JCP.16m11101.
- Rhodes K, Braakhuis A. Performance and Side Effects of Supplementation
with N-Acetylcysteine: A Systematic Review and Meta-Analysis. Sports
Med. 2017;47(8):1619-1636. doi:10.1007/s40279-017-0677-3.